A thyroid-test provider expects quarterly revenue to rise about 15% to 18% year over year
Interpace Biosciences expects Q3 2026 revenue of $10.1M-$10.4M, up 11%-14% from Q2 2026 and 15%-18% year-over-year. The company provides molecular diagnostic tests for thyroid evaluation. Actual results may differ due to ongoing review processes.
How this was made
The 30-second read
Why it matters
The guidance sets expectations for modest growth; investors will watch upcoming full Q3 results for variance.
Market read
Guidance is a primary disclosure for a micro‑cap biotech; relevance is limited to niche investors.
What to watch
Potential reimbursement changes or new test launches could materially affect future revenue.
Background
Interpace Biosciences develops thyroid diagnostic tests (ThyGeNEXT® and ThyraMIR®v2) used for indeterminate thyroid nodules.
Ticker impact
Interpace Biosciences disclosed preliminary Q3 2026 revenue guidance of $10.1M‑$10.4M, indicating 15%‑18% YoY growth.
likely limited upside as investors price in modest growth; pressure if results miss guidance
Revenue guidance is new but the absolute amount is small; market reaction may be muted.
Market effects
Provides a data point for the niche molecular diagnostics sector, but limited broader impact.
Focused on U.S. biotech investors; no significant regional effect.
Minimal global relevance due to company size and niche market.
Counterpoint
If the company can accelerate test adoption, the guidance may understate upside potential.
Key entities
- CompanyInterpace Biosciences, Inc.
Molecular diagnostic firm providing thyroid testing services.